Atlas Trials

Allakos Inc.

18 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Allakos Inc.

RecordFirmDate
Open-Label Extension Study for Subjects With H1 Antihistamine Refractory Chronic Spontaneous Urticaria Completing Study AK006-001 (NCT06577116)Allakos Inc.2024-08-28
Study to Assess the Safety, Tolerability, Pharmacokinetics and Immunogenicity of AK006 in Healthy Subjects and Subjects With Chronic Spontaneous Urticaria (NCT06072157)Allakos Inc.2023-08-28
A Study to Assess Subcutaneous Lirentelimab (AK002) in Chronic Spontaneous Urticaria (NCT05528861)Allakos Inc.2022-10-26
A Study to Assess Subcutaneous Lirentelimab (AK002) in Atopic Dermatitis (NCT05155085)Allakos Inc.2022-06-27
A Study to Assess Subcutaneous AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (NCT05152563)Allakos Inc.2021-12-01
A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Duodenitis (NCT04856891)Allakos Inc.2021-05-20
An Extension Study of Lirentelimab in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis) (NCT04620811)Allakos Inc.2020-12-03
A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Esophagitis (NCT04322708)Allakos Inc.2020-07-06
A Study to Assess AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis) (NCT04322604)Allakos Inc.2020-06-18
A Study to Evaluate Safety, Tolerability, and Bioavailability of Subcutaneous Lirentelimab (AK002) in Adult Healthy Volunteers (NCT04324268)Allakos Inc.2020-03-23
An Extension Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Duodenitis (NCT03664960)Allakos Inc.2018-11-14
A Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis (NCT03496571)Allakos Inc.2018-07-18
A Study of AK002 in Patients With Atopic Keratoconjunctivitis, Vernal Keratoconjunctivitis, and Perennial Allergic Conjunctivitis (NCT03379311)Allakos Inc.2018-02-26
A Study to Assess the Efficacy and Safety of AK002 in Subjects With Antihistamine-Resistant Chronic Urticaria (NCT03436797)Allakos Inc.2018-01-23

Track Allakos Inc. automatically

Every clearance here is in the API, with alerts when new ones post.